Sarepta Therapeutics Inc SRPT

US Biotechnology

$14.86 ▼ -4.50% ($-0.70)

📉 Near 52W Low ⬇️ Below Yest. Low 🔥 High Short Interest 📅 Earnings This Week

Open $15.50

Prev Close $15.56

Day Range $14.84 – $15.65

52W Range $14.68 – $25.32

Market Cap $1.57B

P/E (TTM) 24.12

Beta 0.20

EPS (TTM) $0.07

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1997-06-04
Shares Out.	105,580,000
Website	sarepta.com/ ↗
Phone	16172744000
Employees	835
Revenue	$730.8M
Gross Profit	$622.0M
Net Income	$331.0M
Free Cash Flow	$114.9M
Total Assets	$3.18B
Total Liabilities	$1.67B
Equity	$1.51B

About Sarepta Therapeutics Inc

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Sarepta Therapeutics Inc is a publicly traded company under the ticker symbol SRPT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.